News

Spero Therapeutics raises $30M to support its drug delivery platform targeting Gram-negative bacteria

Cambridge, MA's Spero Therapeutics has raised $30 million in Series B financing to develop its so-called Potentiator Platform to improve existing antibiotics by enabling them to pass through the cell membrane of Gram-negative bacteria.

FDA approves the first extended-release orally disintegrating tablet for ADHD

Neos Therapeutics hopes novel drug delivery will help newly approved Adzenys XR-ODT outcompete generic rivals in the ADHD drug market.

New CRISPR/Cas9 delivery method could offer a clinical pathway

CRISPR/Cas9 gene editing is a rapidly developing technique that is thought to provide revolutionary new ways to manipulate genes for the treatment of a number of diseases. Delivering the CRISPR therapeutic in an efficient, safe and predictable way, though, has been difficult--to this end, researchers at UMass have created a means of administering the gene editor that could help send it to clinical trials.

Mercator launches microinfusion catheter trial for below-the-knee ischemia

California's Mercator MedSystems has begun treating its first patient in an ischemia trial of its microinfusion device that delivers an anti-inflammatory steroid.

Dr. Reddy's wins approval for injectable generic to treat migraines

Hyderabad, India's Dr. Reddy's Laboratories won FDA approval for its generic ZembraceSymTouch injection for adults with migraines that are inadequately managed with existing treatment regimens, such as oral medications.

Aprecia completes $35M financing to support launch of the first 3-D printed medication

3-D printed medicine specialist Aprecia Pharmaceuticals announced that it has completed a $35 million financing round led by Deerfield Management.

Avanir's intranasal migraine med gets past FDA on second try

In 2014, the FDA rejected Avanir Pharmaceutical's intranasal candidate for the treatment of migraines, and called for additional human factors testing of the delivery device. But after a two year delay, the FDA last week approved the med, dubbed Onzetra.

Endangered inhaled insulin player MannKind collaborates with mysterious 'entity' on R&D

MannKind will co-develop several inhaled candidates for conditions such as chronic pain, neurologic diseases and inflammatory disorders with new Seattle-based "entity" Receptor Life Sciences.

Combining light-activated and chemical treatments, new nanoparticles are more effective against tumors

A team of researchers in Massachusetts is developing a two-in-one nanoparticle that delivers both a photodynamic therapy and a molecular therapy to treat highly resistant tumors--such as those associated with pancreatic cancer--with decreased toxicity.

UNC team delivers cancer drugs wrapped in exosomes to cut doses

Researchers at the University of North Carolina have developed a method of drug delivery using exosomes to protect cancer drugs in the body before they reach their target, effectively cutting the necessary dose.

Startup Co-D aims to resuscitate failed BMS drug using polymeric micelle drug delivery

University of Wisconsin-Madison spinout Co-D is deploying its polymeric micelle drug delivery platform with the aim of commercializing a failed Bristol-Myers Squibb cancer drug. So-called Triolimus boasts FDA's orphan drug designation to treat the rare blood vessel cancer angiosarcoma, a milestone that will accelerate its path to FDA approval (or rejection).

Cancer-focused Ensysce Biosciences adds opioid prodrug to its pipeline via merger

Houston's Ensysce Biosciences has merged with Palo Alto, CA's Signature Therapeutics, creating a drug delivery specialist with small and large molecule candidates in the chronic pain and oncology arenas. To be based in San Diego, the combined company will retain the name Ensysce Biosciences.

Svelte Medical announces European launch of low-profile drug-eluting stent

New Providence, NJ's Svelte Medical announced the European launch of the Slender IDS drug-eluting stent, claiming it is the lowest profile device of its kind, resulting in smaller delivery catheter and easier implantation. The device elutes the drug sirolimus.

Spotlight On... Expert says diabetes and rheumatoid arthritis are top therapeutic areas for drug delivery innovation; and more...

Neil Camish of Research Triangle, NC, consultancy International Device Solutions said that therapeutic areas related to drugs that are difficult to deliver manually are the biggest drug delivery...

Catalent to earn up to $618M under antibody-drug conjugate research alliance with Roche

Catalent stands to earn up to $618 million in milestone payments under its research collaboration with Roche, centered around the pharma contractor's SMARTag platform for the creation of antibody drug conjugates.

Takeda teams up with enGene for gastrointestinal gene delivery R&D

Japanese pharma Takeda and Montreal's enGene have teamed up to develop gastrointestinal gene therapies using the latter company's Gene Pill delivery platform.

Will FDA panel's second recommendation of approval for implant to treat opioid addiction be enough?

The first long-acting subdermal implant to treat opioid addiction moved a step closer to FDA approval, when the agency's Psychopharmacologic Drugs Advisory Committee recommended approval of the drug/device combination product by a vote 12-5.

Dental anesthesia delivered via electric current could offer needle-free alternative

The aim in many drug delivery pursuits is to make the patient experience simpler and more comfortable, and one way to make that happen is by going needle-free, especially in the dentist's office. A new study from researchers in Brazil has shown that it's possible to administer anesthetics using an electrical current instead.

Pfizer invests in 4D Molecular Therapeutics, a maker of gene delivery vectors

Pfizer announced earlier this month that it is financing the drug discovery efforts of four early-stage companies to the tune of a combined $46 million, including 4D Molecular Therapeutics, the maker of a platform for the delivery of gene vectors. In addition, the Big Pharma gained an option to exclusively license at least one adeno-associated virus for cardiac disease targets as a result of the transaction.

JPM: Halozyme to focus on its internal pancreatic cancer candidate in 2016

The drug delivery landscape is littered with platform technology companies that fail to achieve commercialization or find a partnership. San Diego's Halozyme is not one of them.